Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Carboplatin + Dostarlimab + Paclitaxel & Endometrial cancer (MMR-d/MSI-H), Carboplatin + Dostarlimab + Paclitaxel is FDA‑approved for Endometrial cancer (MMR-d/MSI-H) (primary advanced or recurrent).
Carboplatin + Dostarlimab + Paclitaxel is EMA‑approved for 1L treatment of dMMR/MSI‑H primary advanced or recurrent endometrial cancer (2).
The clininical phase III, global, double-blind, randomized, placebo-controlled treatment trial NCT03981796 (RUB…